|
|
|
|
|
Tobramycin
drug data and news
Tobramycin drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Tobramycin | ||
| Brand Names/Synonyms | 3'-Deoxykanamycin B; Aktob; CHEMBANK2411; Distobram; Gernebcin; NF 6; Nebcin; Nebramycin; Nebramycin 6; Nebramycin Factir 6; Nebramycin Factor 6; Nebramycin Vi; Obracin; Obramycin; T4014; TOBRAMYCIN; Tenebrimycin; Tenemycin; Tobi; Tobracin; Tobradex; Tobradistin; Tobramaxin; Tobramitsetin; Tobramycetin; Tobramycin 98%; Tobramycin Base; Tobramycin Sulfate; Tobrasone; Tobrex | ||
| Indication | For the treatment of pseudomonas aeruginosa lung infections | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Tobramycin, an aminoglycoside antibiotic obtained from cultures of Streptomyces tenebrarius, is used in combination with other antibiotics to treat urinary tract infections, gynecologic infections, peritonitis, endocarditis, pneumonia, bacteremia and sepsis, respiratory infections including those associated with cystic fibrosis, osteomyelitis, and diabetic foot and other soft-tissue infections. | ||
| Mechanism Of Action | Tobramycin binds irreversibly to one of two aminoglycoside binding sites on the 30 S ribosomal subunit, inhibiting bacterial protein synthesis. Tobramycin may also destabilize bacterial memebrane by binding to 16 S 16 S r-RNA. An active transport mechanism for aminoglycoside uptake is necessary in the bacteria in order to attain a significant intracellular concentration of tobramycin. | ||
| Tobramycin News (When available) |
InSite Vision's AzaSite to Be Highlighted at ARVO Conference; Two ... May 2, 2006 InSite Vision Reports First Quarter 2006 Financial Results May 11, 2006 ISTA Pharmaceuticals, Inc. Reports First Quarter 2006 Financial ... May 8, 2006 ISTA Pharmaceuticals Q1 Net Loss Widens Despite Higher Revenues ... May 8, 2006 | ||
| Dosage Forms | Ophthalmic Ointment; POWDER FOR SOLUTION; Solution for oral inhalation; Ophthalmic Solution; Oral Solution; IV Solution | ||
| Drug_Category | Anti-bacterial Agents; Aminoglycosides; ATC:J01GB01; ATC:S01AA12 | ||
| Absorption | Not Available | ||
| Interactions |
Interactions for Tobramycin: In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME®, Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. Concurrent and/or sequential use of TOBI with other drugs with neurotoxic or ototoxic potential should be avoided. Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol. | ||
| Toxicity | LD50=441mg/kg (s.c. in mice) | ||
| Organisms Affected | Enteric bacteria and other eubacteria | ||
| Chemical IUPAC Name | 4-amino-2-[4,6-diamino-3-[3-amino-6-(aminomethyl)-5-hydroxy-tetrahydropyran-2-yl]oxy-2-hydroxy-cyclohexoxy]-6-(hydroxymethyl)tetrahydropyran-3,5-diol | ||
| Chemical Formula | C18H37N5O9 | ||
| Molecular Weight | 467.515 g/mol | ||
| Smiles String | C1C(C(C(C(C1N)OC2C(C(C(C(O2)CO)O)N)O)O)OC3C(CC(C(O3)CN)O)N)N | ||
| Melting Point | Not Available | ||
| Water Solubility | 1E+003 mg/ml | ||
| State | Solid | ||
| LogP/Hphobicity | -6.899 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not Available | ||
| Half Life | Not Available | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Tobramycin.html http://www.rxlist.com/cgi/generic/tobradex.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00582 | ||
| CAS Registry Number | 32986-56-4 | ||
| KEGG Compound ID | C00397 | ||
| PubChem ID | SID:447098 | ||
| PharmGKB ID | PA451704 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2241209 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |